Nothing Special   »   [go: up one dir, main page]

AR100368A1 - Tratamiento de trastornos respiratorios - Google Patents

Tratamiento de trastornos respiratorios

Info

Publication number
AR100368A1
AR100368A1 ARP150101431A ARP150101431A AR100368A1 AR 100368 A1 AR100368 A1 AR 100368A1 AR P150101431 A ARP150101431 A AR P150101431A AR P150101431 A ARP150101431 A AR P150101431A AR 100368 A1 AR100368 A1 AR 100368A1
Authority
AR
Argentina
Prior art keywords
treatment
lama
composition
inhalable
formoterol
Prior art date
Application number
ARP150101431A
Other languages
English (en)
Inventor
Ullmann Michiel
Original Assignee
Teva Pharmaceuticals Europe B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51032625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR100368(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals Europe B V filed Critical Teva Pharmaceuticals Europe B V
Publication of AR100368A1 publication Critical patent/AR100368A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Producto de combinación que comprende una composición de antagonista muscarínico de acción prolongada inhalable (LAMA) para usar en el tratamiento prolongado de EPOC combinada con una composición de dosis fija inhalable que comprende budesonida y formoterol o una sal farmacéuticamente aceptable de el para la administración según sea necesario (prn) como una medicación de rescate para el tratamiento de exacerbaciones agudas de EPOC. Reivindicación 6: El producto de cualquiera de las reivindicaciones precedentes, caracterizado porque el LAMA es tiotropio. Reivindicación 9: Un estuche que contiene un primer inhalador que contiene una composición de antagonista muscarínico de acción prolongada inhalable (LAMA), un segundo inhalador que contiene una composición de dosis fija inhalable que comprende budesonida y formoterol o una sal farmacéuticamente aceptable de él opcionalmente instrucciones de uso.
ARP150101431A 2014-05-12 2015-05-11 Tratamiento de trastornos respiratorios AR100368A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1408387.7A GB201408387D0 (en) 2014-05-12 2014-05-12 Treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
AR100368A1 true AR100368A1 (es) 2016-09-28

Family

ID=51032625

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP150101431A AR100368A1 (es) 2014-05-12 2015-05-11 Tratamiento de trastornos respiratorios
ARP150101432A AR100369A1 (es) 2014-05-12 2015-05-11 Composición de dosis fija de formoterol y budesonide

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP150101432A AR100369A1 (es) 2014-05-12 2015-05-11 Composición de dosis fija de formoterol y budesonide

Country Status (17)

Country Link
US (2) US20170202858A1 (es)
EP (2) EP3142653A1 (es)
JP (4) JP2017515835A (es)
KR (2) KR20170003600A (es)
CN (2) CN106488770A (es)
AR (2) AR100368A1 (es)
AU (2) AU2015261104A1 (es)
BR (2) BR112016026369A2 (es)
CA (2) CA2948574A1 (es)
CL (1) CL2016002848A1 (es)
EA (2) EA201692276A1 (es)
GB (1) GB201408387D0 (es)
IL (2) IL248875A0 (es)
MX (2) MX2016014695A (es)
PE (1) PE20170073A1 (es)
UA (2) UA119774C2 (es)
WO (2) WO2015173153A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104758294A (zh) * 2014-12-17 2015-07-08 广州呼吸疾病研究所 用于copd、哮喘治疗的吸入药物组合物及其制备方法
TW201735914A (zh) * 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
CN106466322A (zh) * 2016-08-25 2017-03-01 杭州百诚医药科技股份有限公司 一种以布地奈德和噻托溴铵为活性成分的复方制剂
WO2018071443A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
WO2019142214A1 (en) 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
US20200398004A1 (en) * 2018-02-23 2020-12-24 Microdose Therapeutx, Inc. Inhaler and Methods of Use Thereof
CN116077471A (zh) * 2021-11-08 2023-05-09 上海臣邦医药科技股份有限公司 一种供吸入用的粉雾剂组合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2356145A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
EP1086697A2 (en) * 1991-12-18 2001-03-28 AstraZeneca AB New combination of formoterol and budesonide
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
UA80123C2 (en) * 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
US20070293460A1 (en) * 2005-10-31 2007-12-20 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
US20090291146A1 (en) * 2006-08-09 2009-11-26 Glaxo Group Limited Process for manufacturing lactose
EP2327403A3 (en) * 2007-02-19 2011-08-31 Cipla Limited Pharmaceutical combinations of at least two bronchodilators
EP2197444A1 (en) * 2007-09-12 2010-06-23 Glaxo Group Limited Novel combination of therapeutic agents
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
CA2796934C (en) * 2010-04-21 2018-11-20 Chiesi Farmaceutici S.P.A. Process for providing particles with reduced electrostatic charges
EP2593108A2 (en) * 2010-07-16 2013-05-22 Cilpa Limited Pharmaceutical compositions comprising r(+) budesonide and one or more bronchodilators
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
RU2460547C1 (ru) * 2011-04-08 2012-09-10 Валерий Феофанович Ушаков Способ пролонгированной профилактики холодового бронхоспазма у больных с "микст-патологией"
US20150165037A1 (en) * 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo

Also Published As

Publication number Publication date
JP2017515835A (ja) 2017-06-15
WO2015173154A1 (en) 2015-11-19
CA2948574A1 (en) 2015-11-19
AU2015261104A1 (en) 2016-11-17
IL248875A0 (en) 2017-01-31
PE20170073A1 (es) 2017-03-24
JP2017515833A (ja) 2017-06-15
EP3142653A1 (en) 2017-03-22
CL2016002848A1 (es) 2017-07-07
KR20170003601A (ko) 2017-01-09
EP3142654A1 (en) 2017-03-22
GB201408387D0 (en) 2014-06-25
EA201692278A1 (ru) 2017-02-28
BR112016026371A2 (pt) 2018-06-19
CA2948553A1 (en) 2015-11-19
CN106470700A (zh) 2017-03-01
US20170209464A1 (en) 2017-07-27
MX2016014695A (es) 2017-05-04
EA201692276A1 (ru) 2017-03-31
UA119774C2 (uk) 2019-08-12
KR20170003600A (ko) 2017-01-09
US20170202858A1 (en) 2017-07-20
CN106488770A (zh) 2017-03-08
BR112016026369A2 (pt) 2018-05-15
UA119773C2 (uk) 2019-08-12
AR100369A1 (es) 2016-09-28
MX2016014696A (es) 2017-05-04
JP2020023537A (ja) 2020-02-13
AU2015261103A1 (en) 2016-11-17
IL248874A0 (en) 2017-01-31
WO2015173154A9 (en) 2016-03-03
JP2020023536A (ja) 2020-02-13
WO2015173153A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
AR100368A1 (es) Tratamiento de trastornos respiratorios
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
TR201000680A2 (tr) Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
CL2013003497A1 (es) Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
DOP2014000271A (es) Nueva forma de dosificacion y formulacion de abediterol
EP3162804A8 (en) New benzodiazepine derivative and use thereof
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
TR201000623A2 (tr) Yeni tiotropyum kombinasyonu.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
TR201000622A2 (tr) Tiotropyum içeren farmasötik kombinasyonlar.
AR100784A1 (es) Micropartículas multicomponentes para usar en una formulación inhalable, proceso para preparar, formulación farmacéutica, inhalador
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
AR094063A1 (es) Uso de aclidinio, composicion farmaceutica y metodo para mejorar la actividad fisica en pacientes respiratorios
BR112016024510A2 (pt) ?medicamento, uso de brexpiprazol ou de um sal farmaceuticamente aceitável do mesmo, métodos para prevenção ou tratamento de um transtorno relacionado com substância e para produção de uma composição farmacêutica, composição farmacêutica, e, kit?
UY35900A (es) Nueva dosificación y formulación
BR112017005050A2 (pt) composição farmacêutica, nebulizador e método de tratamento ou prevenção de doenças
TR201207226A2 (tr) Yeni inhalasyon aerosol formülasyonlar.
TR201207225A2 (tr) Bir inhalasyon formülasyonu.
TH167850B (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค

Legal Events

Date Code Title Description
FB Suspension of granting procedure